http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 09 Oct 2026 17:22:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++3A++++++++AC+Immune+SA++++++++++++++For%3A+Oct+02++Filed+by%3A+Graney+Thomas/27172351.html si-local-file:///var/storage/secattach/20261009/27172351.html http://www.streetinsider.com/SEC+Filings/Form++3A++++++++AC+Immune+SA++++++++++++++For%3A+Oct+02++Filed+by%3A+Graney+Thomas/27172351.html Fri, 09 Oct 2026 17:22:00 -0400 ACIU http://www.streetinsider.com/SEC+Filings/Form++3++++++++++AC+Immune+SA++++++++++++++For%3A+Oct+02++Filed+by%3A+Graney+Thomas/27169408.html si-local-file:///var/storage/secattach/20261009/27169408.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++AC+Immune+SA++++++++++++++For%3A+Oct+02++Filed+by%3A+Graney+Thomas/27169408.html Fri, 09 Oct 2026 08:08:00 -0400 ACIU http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++AC+Immune+SA++++++++++++++For%3A+Oct+02/27139031.html si-local-file:///var/storage/secattach/20261002/27139031.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++AC+Immune+SA++++++++++++++For%3A+Oct+02/27139031.html Fri, 02 Oct 2026 08:02:00 -0400 ACIU http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+AC+Immune+SA+%28ACIU%29/27098621.html <p>H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $12.00 price target on AC Immune SA (NASDAQ: ACIU).</p><p>The analyst commented: "Yesterday, ACIU reported week-100 results from Part 1 of the VacSYn Phase 2 trial of ACI-7104 in early PD, covering all 34 patients (25 active, nine placebo). All three primary endpoints were met. Immunogenicity was the standout, with 100% of patients developing anti-PD01 IgG after three immunizations, with titers boosted with each successive dose, and the new CRM197 carrier delivering at least a 2-fold improvement over the prior formulation. Importantly we note that the CSF antibody levels were an http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+AC+Immune+SA+%28ACIU%29/27098621.html Thu, 24 Sep 2026 06:48:34 -0400 ACIU http://www.streetinsider.com/FDA/AC+Immune+reports+positive+Phase+2+results+for+Parkinson%27s+vaccine+ACI-7104/27093210.html <p>AC Immune SA (NASDAQ: ACIU) announced positive safety and immunogenicity results through week 100 in Part 1 of VacSYn, its Phase 2 trial of ACI-7104 in patients with early-stage Parkinson's disease.</p> <p>The trial enrolled 34 patients, with 25 receiving ACI-7104 and nine receiving placebo. All primary endpoints for Part 1, which focused on safety, tolerability, and immunogenicity, were met. The drug was reported as generally safe and well tolerated, with 100% of patients developing antibodies against the target antigen PD01 after three immunizations. Antibody penetration into the cerebrospinal fluid (CSF) was observed in all patients.</p> <p>Exploratory analyses showed a signal for total http://www.streetinsider.com/FDA/AC+Immune+reports+positive+Phase+2+results+for+Parkinson%27s+vaccine+ACI-7104/27093210.html Wed, 23 Sep 2026 07:02:10 -0400 ACIU http://www.streetinsider.com/FDA/AC+Immune+reports+positive+week-100+data+for+Parkinson%27s+vaccine+trial/27093152.html <p>AC Immune SA (NASDAQ: ACIU) announced positive safety and immunogenicity results through week-100 in Part 1 of VacSYn, a randomized, double-blind, placebo-controlled Phase 2 trial of ACI-7104 in patients with early-stage Parkinson's disease.</p> <p>All primary endpoints for Part 1 were met. ACI-7104 was reported to be generally safe and well-tolerated, with 100% of patients developing antibodies against the target antigen PD01 after three immunizations. The Part 1 data includes results from all 34 patients randomized into the study, with 25 receiving ACI-7104 and nine receiving placebo.</p> <p>Robust antibody penetration into the cerebrospinal fluid was observed in all patients. Exploratory analyses showed a http://www.streetinsider.com/FDA/AC+Immune+reports+positive+week-100+data+for+Parkinson%27s+vaccine+trial/27093152.html Wed, 23 Sep 2026 07:00:16 -0400 ACIU http://www.streetinsider.com/Press+Releases/AC+Immune+Reports+Positive+Safety+%26+Immunogenicity+at+week-100+in+Part+1+of+VacSYn+Phase+2+Trial+of+ACI-7104/27093108.html <ul><li style="margin-top:0cm; margin-bottom:0cm;"><i>All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated </i></li><li style="margin-top:0cm; margin-bottom:0cm;"><i>Strong immunogenicity demonstrated, with 100% response rate after three immunizations</i></li><li style="margin-top:0cm; margin-bottom:0cm;"><i>Clear antibody penetration into the </i><i>cerebrospinal fluid (CSF) and signals for target engagement </i></li><li style="margin-top:0cm; margin-bottom:0cm;"><i>Discussions with FDA regarding future development path planned for early 2027 </i></li><li style="margin-top:0cm; margin-bottom:0cm;"><i>AC Immune to host webcast &amp; conference call today at 10:00am EDT / 16:00 CEST details below</i></li></ul> <p align="justify"><b>Lausanne, Switzerland, September 23, 2026</b> – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative http://www.streetinsider.com/Press+Releases/AC+Immune+Reports+Positive+Safety+%26+Immunogenicity+at+week-100+in+Part+1+of+VacSYn+Phase+2+Trial+of+ACI-7104/27093108.html Wed, 23 Sep 2026 07:00:00 -0400 ACIU http://www.streetinsider.com/Globe+Newswire/AC+Immune+Reports+Positive+Safety+%26+Immunogenicity+at+week-100+in+Part+1+of+VacSYn+Phase+2+Trial+of+ACI-7104/27093108.html <ul><li style="margin-top:0cm; margin-bottom:0cm;"><i>All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated </i></li><li style="margin-top:0cm; margin-bottom:0cm;"><i>Strong immunogenicity demonstrated, with 100% response rate after three immunizations</i></li><li style="margin-top:0cm; margin-bottom:0cm;"><i>Clear antibody penetration into the </i><i>cerebrospinal fluid (CSF) and signals for target engagement </i></li><li style="margin-top:0cm; margin-bottom:0cm;"><i>Discussions with FDA regarding future development path planned for early 2027 </i></li><li style="margin-top:0cm; margin-bottom:0cm;"><i>AC Immune to host webcast &amp; conference call today at 10:00am EDT / 16:00 CEST details below</i></li></ul> <p align="justify"><b>Lausanne, Switzerland, September 23, 2026</b> – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative http://www.streetinsider.com/Globe+Newswire/AC+Immune+Reports+Positive+Safety+%26+Immunogenicity+at+week-100+in+Part+1+of+VacSYn+Phase+2+Trial+of+ACI-7104/27093108.html Wed, 23 Sep 2026 07:00:00 -0400 ACIU http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++AC+Immune+SA++++++++++++++For%3A+Sep+23/27093170.html si-local-file:///var/storage/secattach/20260923/27093170.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++AC+Immune+SA++++++++++++++For%3A+Sep+23/27093170.html Wed, 23 Sep 2026 07:00:00 -0400 ACIU http://www.streetinsider.com/Press+Releases/AC+Immune+Reports+Positive+Safety+%26amp%3B+Immunogenicity+at+week-100+in+Part+1+of+VacSYn+Phase+2+Trial+of+ACI-7104/27093172.html <ul><li style="margin-top:0cm; margin-bottom:0cm;"><i>All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated </i></li><li style="margin-top:0cm; margin-bottom:0cm;"><i>Strong immunogenicity demonstrated, with 100% response rate after three immunizations</i></li><li style="margin-top:0cm; margin-bottom:0cm;"><i>Clear antibody penetration into the </i><i>cerebrospinal fluid (CSF) and signals for target engagement </i></li><li style="margin-top:0cm; margin-bottom:0cm;"><i>Discussions with FDA regarding future development path planned for early 2027 </i></li><li style="margin-top:0cm; margin-bottom:0cm;"><i>AC Immune to host webcast &amp; conference call today at 10:00am EDT / 16:00 CEST details below</i></li></ul> <p align="justify"><b>Lausanne, Switzerland, September 23, 2026</b> – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative http://www.streetinsider.com/Press+Releases/AC+Immune+Reports+Positive+Safety+%26amp%3B+Immunogenicity+at+week-100+in+Part+1+of+VacSYn+Phase+2+Trial+of+ACI-7104/27093172.html Wed, 23 Sep 2026 07:00:00 -0400 ACIU http://www.streetinsider.com/Globe+Newswire/AC+Immune+Reports+Positive+Safety+%26amp%3B+Immunogenicity+at+week-100+in+Part+1+of+VacSYn+Phase+2+Trial+of+ACI-7104/27093172.html <ul><li style="margin-top:0cm; margin-bottom:0cm;"><i>All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated </i></li><li style="margin-top:0cm; margin-bottom:0cm;"><i>Strong immunogenicity demonstrated, with 100% response rate after three immunizations</i></li><li style="margin-top:0cm; margin-bottom:0cm;"><i>Clear antibody penetration into the </i><i>cerebrospinal fluid (CSF) and signals for target engagement </i></li><li style="margin-top:0cm; margin-bottom:0cm;"><i>Discussions with FDA regarding future development path planned for early 2027 </i></li><li style="margin-top:0cm; margin-bottom:0cm;"><i>AC Immune to host webcast &amp; conference call today at 10:00am EDT / 16:00 CEST details below</i></li></ul> <p align="justify"><b>Lausanne, Switzerland, September 23, 2026</b> – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative http://www.streetinsider.com/Globe+Newswire/AC+Immune+Reports+Positive+Safety+%26amp%3B+Immunogenicity+at+week-100+in+Part+1+of+VacSYn+Phase+2+Trial+of+ACI-7104/27093172.html Wed, 23 Sep 2026 07:00:00 -0400 ACIU http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+AC+Immune+SA+%28ACIU%29/26963970.html <p>H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $12.00 price target on AC Immune SA (NASDAQ: ACIU).</p><p>The analyst commented: "On August 20, ACI-19764 delivered the first of a two-part Phase 1 readout, in which we believe the CNS exposure data is the key data point to focus on. The company confirmed brain penetration via CSF exposure, with daily doses of ≤10mg exceeding the IC90 and blinded whole-blood assay data showing dose-dependent IL-1β inhibition. That said, the number we would like to see is CSF IC90 coverage, because it is brain exposure that determines whether the central target is http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+AC+Immune+SA+%28ACIU%29/26963970.html Mon, 24 Aug 2026 06:55:10 -0400 ACIU http://www.streetinsider.com/FDA/AC+Immune+reports+early+Phase+1+data+for+NLRP3+inhibitor+ACI-19764/26952607.html <p>AC Immune SA (NASDAQ: ACIU) announced preliminary results from a Phase 1 first-in-human clinical study of ACI-19764, an oral small molecule inhibitor of the NLRP3 inflammasome, according to a company statement.</p> <p>The study, conducted in healthy volunteers in Europe, evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics across single ascending dose and multiple ascending dose cohorts. ACI-19764 was reported as safe and well-tolerated at doses up to 20mg per day, with a serum half-life greater than 30 hours. No serious adverse events or treatment withdrawals were recorded. Cerebrospinal fluid exposure confirmed brain penetration of the compound.</p> <p>Pharmacokinetic data indicated that daily doses of 10mg http://www.streetinsider.com/FDA/AC+Immune+reports+early+Phase+1+data+for+NLRP3+inhibitor+ACI-19764/26952607.html Thu, 20 Aug 2026 07:00:16 -0400 ACIU http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++AC+Immune+SA++++++++++++++For%3A+Aug+20/26952622.html si-local-file:///var/storage/secattach/20260820/26952622.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++AC+Immune+SA++++++++++++++For%3A+Aug+20/26952622.html Thu, 20 Aug 2026 07:00:00 -0400 ACIU O.03555561 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++AC+Immune+SA++++++++++++++For%3A+Aug+20/26952622.html si-local-file:///var/storage/secattach/20260820/26952622.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++AC+Immune+SA++++++++++++++For%3A+Aug+20/26952622.html Thu, 20 Aug 2026 07:00:00 -0400 ACIU O.03555561 http://www.streetinsider.com/Press+Releases/AC+Immune+Announces+Positive+Preliminary+Phase+1+Data+for+NLRP3+Inhibitor+ACI-19764/26952562.html <p align="center"><b>AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764</b></p> <ul type="disc"><li><i>ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome </i></li><li><i>Preliminary data showed ACI-19764 was safe and well tolerated across single and multiple ascending dose cohorts with confirmed CSF penetration</i></li><li><i>Based on PK data the therapeutic dose is expected to be ≤10mg once daily</i></li><li><i>To rapidly evaluate the anti-inflammatory activity of ACI-19764 (effect on hsCRP), dosing of a cardiovascular risk cohort is now underway with initial results expected by year end</i></li><li><i>Full results from the Phase 1/1b trial are expected in H1 2027</i><br /><br /></li></ul> <p align="justify"><b>Lausanne, http://www.streetinsider.com/Press+Releases/AC+Immune+Announces+Positive+Preliminary+Phase+1+Data+for+NLRP3+Inhibitor+ACI-19764/26952562.html Thu, 20 Aug 2026 07:00:00 -0400 ACIU ACIU http://www.streetinsider.com/Globe+Newswire/AC+Immune+Announces+Positive+Preliminary+Phase+1+Data+for+NLRP3+Inhibitor+ACI-19764/26952562.html <p align="center"><b>AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764</b></p> <ul type="disc"><li><i>ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome </i></li><li><i>Preliminary data showed ACI-19764 was safe and well tolerated across single and multiple ascending dose cohorts with confirmed CSF penetration</i></li><li><i>Based on PK data the therapeutic dose is expected to be ≤10mg once daily</i></li><li><i>To rapidly evaluate the anti-inflammatory activity of ACI-19764 (effect on hsCRP), dosing of a cardiovascular risk cohort is now underway with initial results expected by year end</i></li><li><i>Full results from the Phase 1/1b trial are expected in H1 2027</i><br /><br /></li></ul> <p align="justify"><b>Lausanne, http://www.streetinsider.com/Globe+Newswire/AC+Immune+Announces+Positive+Preliminary+Phase+1+Data+for+NLRP3+Inhibitor+ACI-19764/26952562.html Thu, 20 Aug 2026 07:00:00 -0400 ACIU ACIU http://www.streetinsider.com/Press+Releases/AC+Immune+Announces+Positive+Preliminary+Phase+1+Data+for+NLRP3+Inhibitor+ACI-19764/26952562.html <p align="center"><b>AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764</b></p> <ul type="disc"><li><i>ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome </i></li><li><i>Preliminary data showed ACI-19764 was safe and well tolerated across single and multiple ascending dose cohorts with confirmed CSF penetration</i></li><li><i>Based on PK data the therapeutic dose is expected to be ≤10mg once daily</i></li><li><i>To rapidly evaluate the anti-inflammatory activity of ACI-19764 (effect on hsCRP), dosing of a cardiovascular risk cohort is now underway with initial results expected by year end</i></li><li><i>Full results from the Phase 1/1b trial are expected in H1 2027</i><br /><br /></li></ul> <p align="justify"><b>Lausanne, http://www.streetinsider.com/Press+Releases/AC+Immune+Announces+Positive+Preliminary+Phase+1+Data+for+NLRP3+Inhibitor+ACI-19764/26952562.html Thu, 20 Aug 2026 07:00:00 -0400 ACIU ACIU http://www.streetinsider.com/Globe+Newswire/AC+Immune+Announces+Positive+Preliminary+Phase+1+Data+for+NLRP3+Inhibitor+ACI-19764/26952562.html <p align="center"><b>AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764</b></p> <ul type="disc"><li><i>ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome </i></li><li><i>Preliminary data showed ACI-19764 was safe and well tolerated across single and multiple ascending dose cohorts with confirmed CSF penetration</i></li><li><i>Based on PK data the therapeutic dose is expected to be ≤10mg once daily</i></li><li><i>To rapidly evaluate the anti-inflammatory activity of ACI-19764 (effect on hsCRP), dosing of a cardiovascular risk cohort is now underway with initial results expected by year end</i></li><li><i>Full results from the Phase 1/1b trial are expected in H1 2027</i><br /><br /></li></ul> <p align="justify"><b>Lausanne, http://www.streetinsider.com/Globe+Newswire/AC+Immune+Announces+Positive+Preliminary+Phase+1+Data+for+NLRP3+Inhibitor+ACI-19764/26952562.html Thu, 20 Aug 2026 07:00:00 -0400 ACIU ACIU http://www.streetinsider.com/FDA/AC+Immune+gets+FDA+fast+track+for+Parkinson%27s+drug+ACI-7104/26901058.html <p>AC Immune SA (NASDAQ: ACIU) announced it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACI-7104, its anti-alpha-synuclein active immunotherapy candidate for early-stage Parkinson's disease, according to a company statement dated August 11, 2026.</p> <p>The FDA also cleared the company's Investigational New Drug (IND) application for ACI-7104, allowing the ongoing Phase 2 VacSYn trial to expand to sites in the United States. The Lausanne, Switzerland-based company said full week-100 results from Part 1 of the VacSYn trial are expected in the second half of 2026.</p> <p>ACI-7104 is designed to induce antibodies that preferentially recognize aggregated alpha-synuclein http://www.streetinsider.com/FDA/AC+Immune+gets+FDA+fast+track+for+Parkinson%27s+drug+ACI-7104/26901058.html Tue, 11 Aug 2026 07:00:13 -0400 ACIU http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++AC+Immune+SA++++++++++++++For%3A+Aug+11/26901120.html si-local-file:///var/storage/secattach/20260811/26901120.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++AC+Immune+SA++++++++++++++For%3A+Aug+11/26901120.html Tue, 11 Aug 2026 07:00:00 -0400 ACIU O.03555561 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++AC+Immune+SA++++++++++++++For%3A+Aug+11/26901120.html si-local-file:///var/storage/secattach/20260811/26901120.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++AC+Immune+SA++++++++++++++For%3A+Aug+11/26901120.html Tue, 11 Aug 2026 07:00:00 -0400 ACIU O.03555561 http://www.streetinsider.com/Press+Releases/AC+Immune+Receives+FDA+Fast+Track+Designation+for+Anti-Alpha-synuclein+Active+Immunotherapy%2C+ACI-7104%2C+to+Treat+Early+Parkinson%E2%80%99s+Disease+%28PD%29/26901000.html <p align="center"><b>AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)</b></p> <ul type="disc"><li>Ongoing Phase 2 VacSYn study to expand to sites in USA with Investigational New Drug (IND) clearance</li><li>Recent positive interim results showed safety and immunogenicity with early signals of activity</li><li>Full week-100 results from Part 1 of VacSYn trial expected in H2 2026<br /><br /></li></ul> <p align="justify"><b>Lausanne, Switzerland, August 11, 2026</b> – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today announced that it has received Fast Track designation and clearance of its http://www.streetinsider.com/Press+Releases/AC+Immune+Receives+FDA+Fast+Track+Designation+for+Anti-Alpha-synuclein+Active+Immunotherapy%2C+ACI-7104%2C+to+Treat+Early+Parkinson%E2%80%99s+Disease+%28PD%29/26901000.html Tue, 11 Aug 2026 07:00:00 -0400 ACIU ACIU http://www.streetinsider.com/Globe+Newswire/AC+Immune+Receives+FDA+Fast+Track+Designation+for+Anti-Alpha-synuclein+Active+Immunotherapy%2C+ACI-7104%2C+to+Treat+Early+Parkinson%E2%80%99s+Disease+%28PD%29/26901000.html <p align="center"><b>AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)</b></p> <ul type="disc"><li>Ongoing Phase 2 VacSYn study to expand to sites in USA with Investigational New Drug (IND) clearance</li><li>Recent positive interim results showed safety and immunogenicity with early signals of activity</li><li>Full week-100 results from Part 1 of VacSYn trial expected in H2 2026<br /><br /></li></ul> <p align="justify"><b>Lausanne, Switzerland, August 11, 2026</b> – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today announced that it has received Fast Track designation and clearance of its http://www.streetinsider.com/Globe+Newswire/AC+Immune+Receives+FDA+Fast+Track+Designation+for+Anti-Alpha-synuclein+Active+Immunotherapy%2C+ACI-7104%2C+to+Treat+Early+Parkinson%E2%80%99s+Disease+%28PD%29/26901000.html Tue, 11 Aug 2026 07:00:00 -0400 ACIU ACIU http://www.streetinsider.com/Press+Releases/AC+Immune+Receives+FDA+Fast+Track+Designation+for+Anti-Alpha-synuclein+Active+Immunotherapy%2C+ACI-7104%2C+to+Treat+Early+Parkinson%E2%80%99s+Disease+%28PD%29/26901000.html <p align="center"><b>AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)</b></p> <ul type="disc"><li>Ongoing Phase 2 VacSYn study to expand to sites in USA with Investigational New Drug (IND) clearance</li><li>Recent positive interim results showed safety and immunogenicity with early signals of activity</li><li>Full week-100 results from Part 1 of VacSYn trial expected in H2 2026<br /><br /></li></ul> <p align="justify"><b>Lausanne, Switzerland, August 11, 2026</b> – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today announced that it has received Fast Track designation and clearance of its http://www.streetinsider.com/Press+Releases/AC+Immune+Receives+FDA+Fast+Track+Designation+for+Anti-Alpha-synuclein+Active+Immunotherapy%2C+ACI-7104%2C+to+Treat+Early+Parkinson%E2%80%99s+Disease+%28PD%29/26901000.html Tue, 11 Aug 2026 07:00:00 -0400 ACIU ACIU